Stakeholder Forum 2012
Over 150 people attended IMI's annual Stakeholder Forum at the Husa President Park Hotel [1] in Brussels, Belgium on Wednesday 30 May 2012.
Videos of the event can be viewed on IMI's YouTube Channel [2]
The event featured:
- presentations on IMI project successes
- an overview of IMI’s recently-launched projects
- an update on IMI’s efforts to simplify procedures
- a debate on IMI’s impact on the pharmaceutical research and development (R&D) landscape
- workshops on the following topics from current and future IMI Calls for proposals [3]:
- antimicrobial resistance - the final Call text is now available via the 6th Call section [4]
- vaccines - a draft outline of the indicative Call text is now available on the Future Topics page [3]
- effectiveness research - networking opportunities
Agenda 
[5]
Presentations
Plenary Session
Welcome and introduction [6]
Michel Goldman, Executive Director, IMI
eTOX – Data integration for in silico toxicity prediction [7]
Gerhard Ecker, University of Vienna
Ferran Sanz, IMIM - Universitat Pompeu Fabra
Open PHACTS – the Open Pharmacological Concepts Triple Store [8]
Gerhard Ecker, University of Vienna
Bryn Williams-Jones, Connected Discovery Ltd
Patient involvement in the PROactive project [9]
Pim De Boer, Netherlands Asthma Foundation
IMI Education and Training: www.on-course.eu [10]
Ghazaleh Gouya, Medical University Vienna
Introduction to IMI’s newest projects [11]
Michel Goldman, Executive Director, IMI
Introduction to EUPATI [12]
Nicola Bedlington, European Patients’ Forum
IMI’s simplified procedures [13]
Nathalie Seigneuret, Senior Scientific Project Manager, IMI
Ana Padrão, IT Manager, IMI
Magali Poinot, Legal Manager, IMI
Workshop: Combating Antibiotic Resistance
Introduction [14]
Michel Goldman, Executive Director, IMI
Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) [15]
David Payne, GlaxoSmithKline
IMI’s 6th Call for proposals - Procedures & Practicalities [16]
Nathalie Seigneuret, Scientific Project Manager, IMI
Maria Teresa De Magistris, Principal Scientific Manager, IMI
Workshop: Vaccines & Effectiveness research
Introduction [17]
Ann Martin, Principal Scientific Manager, IMI
Fatiha Sadallah, Principal Scientific Manager, IMI
Building a sustainable framework for rapid assessment of vaccination benefit/risk in Europe [18]
Vincent Bauchau, GSK Biologicals
Incorporating relative effectiveness research into development strategies [19]
Chris Chinn, GlaxoSmithKline, European Pharmaceuticals
[20]